Venenum Biodesign

Venenum Biodesign is a preclinical-stage biotechnology company leveraging its proprietary ECLiPS screening technology and a 5.5-million-compound library to discover novel small molecule drugs. Its research is concentrated on two core therapeutic areas: immuno-oncology and metabolic disease, with two lead-stage programs advancing toward developmental candidates. Operating within the integrated Genesis Drug Discovery & Development (GD3) CRO network, the company combines internal discovery capabilities with a partnership-based business model to de-risk and advance its pipeline.

Proprietary ECLiPS screening technology combined with an ultra-high-throughput screening (UHTS) platform and a proprietary library of over 5.5 million small molecules. Supported by integrated in-house capabilities in protein engineering, structural biology, and medicinal chemistry.

Operates in highly competitive spaces against large pharmaceutical companies and well-funded biotechs. Differentiation relies on its unique compound library, screening technology, and integrated discovery capabilities within the GBG network. Its hybrid model as both a drug discoverer and a service provider is a distinct positioning.